Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

1.340 -0.060 (-4.29%)
Delayed Quote Updated: 3:02 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cellectis Touts Positive Preliminary Data From Two Leukemia Trials ↗
 
Via Benzinga
News headline image
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
From Cellectis Inc.
Via GlobeNewswire
News headline image
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers ↗
 
Via Benzinga
News headline image
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis's Earnings Outlook ↗
Cellectis (NASDAQ:CLLS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Cellectis will... 
Via Benzinga
News headline image
Cellectis to Report Third Quarter 2022 Financial Results
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket ↗
Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Akanda (NASDAQ:AKAN) stock rose 27.1% to $0.52 during Friday's pre-market session. The company's market cap stands at $16.0 million. 
Via Benzinga
News headline image
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday ↗
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. 
Via Benzinga
News headline image
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day... 
Via Benzinga
News headline image
11 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
News headline image
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket ↗
Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading. 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study ↗
The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis' (NASDAQ: CLLS) Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
38 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for... 
Via Benzinga
News headline image
71 Biggest Movers From Yesterday ↗
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Natural Killer Cell Therapy Focused-Cytovia Turns To SPAC Merger For Public Market Debut ↗
 
Via Benzinga
News headline image
Cellectis Reveals Preclinical Data On First Allogeneic Dual CAR T-Cell Product In Non-Hodgkin Lymphoma ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.